KM Biologics Co. Ltd. products

A hepatitis A vaccine produced by culturing hepatitis A virus on African green monkey kidney GL37 cells, followed by purification and inactivation. Aimmugen was developed in Japan. It is lyophilized and contains no adjuvants. Aimmugen can be administered subcutaneously or intramuscularly to people of all ages. General immunization requires 3 administrations, however, when rapid immunization is needed, 2 administrations at 0 and 2 weeks may be adequate.

Bimmugen contains hepatitis B virus surface antigens (HBs antigen) prepared from yeast using recombinant technology. Bimmugen can be used not only to prevent hepatitis B infection, but also to prevent maternal transmission and for post-exposure prophylaxis.

In additions to protective antigens against Bordetella pertussis, diphtheria toxoid and tetanus toxoid, Quattrovac also contains inactivated poliovirus types 1, 2 and 3 derived from Sabin strains. Quattrovac does not contain thimerosal or other preservatives, and is provided in an easy to use syringe.

An inactivated quadrivalent split (HA) seasonal influenza vaccine produced using embryonated chicken eggs. The vaccine contains 15 μg or more of HA proteins for each strain per adult dose. The strains used to make the vaccine are decided by the MHLW each year.

This product is a lyophilized diphtheria antitoxin produced by collecting and purifying plasma from horses immunized with diphtheria toxoid. It is highly stable thanks to its lyophilized form, and can be stored for up to ten years. When reconstituted with 10 mL of the attached diluent, the product contains the following active ingredients per mL: 500 units or more of diphtheria antitoxin.

This product contains lyophilized botulism type A, B, E and F antitoxin produced by collecting and purifying plasma from horses immunized with type A, B, E and F botulinum toxoid. It is highly stable thanks to its lyophilized form, and can be stored for up to ten years. When reconstituted with 20 mL of the attached diluent, the product contains the following active ingredients per mL: 500 units or more of botulism type A, B, and E antitoxin 200 units or more of botulism type F antitoxin.

This product is a lyophilized gas gangrene antitoxin produced by collecting and purifying plasma from horses immunized with gas gangrene toxoid. It is highly stable thanks to its lyophilized form, and can be stored for up to ten years. When reconstituted with 20 mL of the attached diluent, the product contains the following active ingredients per mL: 500 units or more of Clostridium perfringens Type A antitoxin, Clostridium septicum antitoxin and Clostridium oedematiens antitoxin.

This product is a lyophilized Mamushi antivenom produced by collecting and purifying serum from horses immunized with Mamushi venom and toxoid. It is highly stable thanks to its lyophilized form, and can be stored for up to ten years. When reconstituted with 20 mL of the attached diluent, the product contains the following active ingredients per mL: 300 units or more (Anti-lethal toxin, Anti-hemorrhagic I toxin) of Mamushi antivenom.

This product is a lyophilized Habu antivenom produced by collecting and purifying serum from horses immunized with Habu venom and toxoid. It is highly stable thanks to its lyophilized form, and can be stored for up to ten years. When reconstituted with 20 mL of the attached diluent, the product contains the following active ingredients per mL: 300 units or more (Anti-lethal toxin, Anti-hemorrhagic I & II toxin) of Habu antivenom.